Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 18, 2014, 11:32:21 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 649733
  • Total Topics: 49589
  • Online Today: 284
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Atripla vs. Quad News  (Read 1157 times)

0 Members and 1 Guest are viewing this topic.

Offline cjmchgo

  • Member
  • Posts: 38
  • Dx 1992
Atripla vs. Quad News
« on: March 07, 2012, 04:53:51 PM »
SEATTLE (Reuters) - Full details from a pivotal trial of Gilead Sciences Inc experimental Quad HIV pill show that it caused fewer adverse side effects than the company's current three-drug pill, Atripla.

Gilead said last year that the trial had met its goal of showing that the four-drug Quad worked as well as Atripla in controlling levels of the virus that causes AIDS.

The safety data, presented here on Wednesday at the Conference on Retroviruses and Opportunistic Infections, showed that patients on Atripla had significantly higher rates of dizziness, abnormal dreams, insomnia and rash, compared with the Quad. The experimental pill did result in higher rates of nausea, 21 percent vs 14 percent.

The study found that at 48 weeks of treatment, 88 percent of Quad patients, compared with 84 percent of Atripla patients, achieved target levels of HIV virus.

Discontinuation rates were similar for both arms of the study, said Dr. Paul Sax, clinical director of the division of infectious diseases at Brigham and Women's Hospital in Boston and the study's lead investigator.

He said 1.4 percent of patients in the Quad group dropped out due to kidney abnormalities, while 1.4 percent of the Atripla group discontinued due to rash.

Dr. Sax said the median level of serum creatinine increase -- a measure of renal toxicity -- was 0.14 milligrams per deciliter for the Quad arm of the study, which was below the level of 0.4 mg/dL which would have been a safety concern.

On the issue of whether it would make sense to eventually switch patients from Atripla to the Quad, he said "it looks like a switch would be virologically safe and maybe associated with fewer central nervous system side effects."

The Quad is seen as key to Gilead's continued dominance of the market for HIV drugs. It combines experimental integrase inhibitor elvitegravir and boosting agent cobicistat with Truvada, a pill consisting of Gilead's older HIV drugs Emtriva and Viread.

Most of the company's current drug sales, which totaled $8.1 billion last year, come from Atripla, a once-daily pill that combines Truvada with Bristol-Myers Squibb's Sustiva.

With the Quad, which is currently under review by U.S. regulators, Gilead owns all of the components.

Full results from another successful trial comparing the Quad to a combination of ritonavir-boosted Reyataz, a protease inhibitor sold by Bristol-Myers, and Truvada, will be presented at the Seattle conference on Thursday.

The Food and Drug Administration is due to decide by August 27 whether to approve the four-drug HIV pill.

(Reporting By Deena Beasley; Editing by Tim Dobbyn)
April/May, 1992: Infected at age 21
Aug 31, 1992: Tested positive
Sep 8, 1992 T-cells 977, 43%
1993-1998: T-cells 675-800
1999-2001: T-cells 500-600
2000-2004: T-cells 425-525 23% VL 500-2000
2005-2008: T-cells 275-375, 20%, VL 950-2500
December 2008: Started Atripla
Dec 2009: T-cells 637, 33%, VL UD
Dec 2010: T-cells 544, 35%, VL UD
Dec 2011: T-cells 596, 41%, VL UD
January 2, 2012 stopped Atripla (CNS issues)
January 4, 2012 started Isentress/Truvada
March 25, 2014 Still on I/T t-cells 673, VL undetectable

Offline mikeyb39

  • Member
  • Posts: 948
Re: Atripla vs. Quad News
« Reply #1 on: March 07, 2012, 08:24:37 PM »
It would be nice if they would come up with something new that didn't include Truvada.  Truvada doesn't agree with me very well.  Seems like all the  new medications coming out have Truvada in them.  My nerves seem to have a big issue with it.
11/02/2010  cd4-251, vl-591000
12/09/2010  started Atripla
02/18/2011  cd4-425, vl-800
06/10/2011  cd4-447, vl-70
10/10/2011  cd4-666, vl-80
01/05/2012  swiched med (prezista,norvir ,isentress, )
02/10/2012  cd4-733, vl-UD  Viread removed
06/10/2012  cd4-614, vl-UD
12/14/2012  cd4-764, vl-UD
09/01/2013  cd4-785, vl-UD
03/06/2014. cd4- 1078, VL-UD
09/05/2014  cd4-850 , VL-UD

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.